Incidence of acute haemolytic transfusion reaction among ABO-incompatible recipients transfused with A
acute haemolytic transfusion reaction
blood group incompatibility
haemovigilance
red blood cell transfusion
weak ABO subgroups
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
06
07
2023
received:
04
05
2023
accepted:
10
07
2023
medline:
23
10
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
ABO antigens are among the most immunogenic, but the haemolytic risks of ABO incompatibilities involving a donor with a weak ABO phenotype are little documented. This retrospective case series assessed the incidence of acute haemolytic transfusion reaction (AHTR) among ABO-incompatible recipients of A Nine donors initially typed as Group B (N = 1) or O (N = 8) were subsequently found to display an A In this case series, no conclusive evidence of serious AHTR was found among ABO-incompatible recipients who were inadvertently transfused with A
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
ABO antigens are among the most immunogenic, but the haemolytic risks of ABO incompatibilities involving a donor with a weak ABO phenotype are little documented.
MATERIALS AND METHODS
METHODS
This retrospective case series assessed the incidence of acute haemolytic transfusion reaction (AHTR) among ABO-incompatible recipients of A
RESULTS
RESULTS
Nine donors initially typed as Group B (N = 1) or O (N = 8) were subsequently found to display an A
CONCLUSION
CONCLUSIONS
In this case series, no conclusive evidence of serious AHTR was found among ABO-incompatible recipients who were inadvertently transfused with A
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
854-862Subventions
Organisme : This study was funded by Héma-Québec.
Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. N Engl J Med. 2019;381:150-162.
Delaney M, Wendel S, Bercovitz RS, Cid J, Cohn C, Dunbar NM, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388:2825-2836.
Levy JH, McKee A. Chapter 30-bleeding, hemostasis, and transfusion medicine. In: Sidebotham D, Mckee A, Gillham M, Levy JH, editors. Cardiothoracic critical care. Philadelphia, PA: Butterworth-Heinemann; 2007. p. 437-460.
Comité de Biovigilance du Québec. Rapport 2016-2017. [cited 2022 Jan 11]. Available from: https://publications.msss.gouv.qc.ca/msss/fichiers/2020/20-933-03W.pdf
Thakral B, Saluja K, Bajpai M, Sharma RR, Marwaha N. Importance of weak ABO subgroups. Lab Med. 2005;36:32-34.
Schmidt PJ, Nancarrow JF, Morrison EG, Chase C. A hemolytic reaction due to the transfusion of Ax blood. J Lab Clin Med. 1959;54:38-41.
Goebel M, Halm-Heinrich I, Parkner A, Rink G, Heim MU, Bugert P. A novel ABO gene variant leads to discrepant results in forward/reverse and molecular blood grouping. Transfus Med Hemother. 2013;40:454-458.
Institut National de Santé Publique du Québec. Guide de déclaration des événements indésirables associés à la transfusion de produits sanguins. 2017.
Choosing Wisely Canada. Why give two when one will do?-A toolkit for reducing unnecessary red blood cell transfusions in hospitals. 2019.
Nawej KI, Lambert G, Unité Surveillance, Évaluation de Risque et Contrôle des Maladies Infectieuses, Direction des Risques Biologiques. Surveillance des erreurs et réactions transfusionnelles au Québec. 2019 [cited 2023 Feb 6]. Available from: https://www.inspq.qc.ca/sites/default/files/publications/2860-surveillance-erreurs-rections-transfusionnelles-2019.pdf
Serious Hazards of Transfusion (SHOT). Annual Shot Report 2019. [cited 2023 Feb 6]. Available from: https://www.shotuk.org/shot-reports/report-summary-and-supplement-2019/
Centers for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. 2021.
Serious Hazards of Transfusion. Definitions of current SHOT reporting categories & what to report. 2021 [cited 2022 Jan 11]. Available from: https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-V6-19.10.21.pdf
Garretta M, Muller A, Gener J, Matte C, Moullec J. Reliability in automatic determination of the ABO group by the groupamatic system. Vox Sang. 1974;27:141-155.
Kaur G, Kaur P, Basu S, Kaur R. Blood group discrepancies at a tertiary care centre-analysis and resolution. Int J Lab Hematol. 2014;36:481-487.
Yamamoto F, McNeil PD, Yamamoto M, Hakomori S, Harris T, Judd WJ, et al. Molecular genetic analysis of the ABO blood group system: 1. Weak subgroups: A3 and B3 alleles. Vox Sang. 1993;64:116-119.
Cartron JP, Gerbal A, Hughes-Jones NC, Salmon C. Weak A' phenotypes: relationship between red cell agglutinability and antigen site density. Immunology. 1974;27:723-727.
Heier HE, Namork E, Čalkovská Z, Sandin R, Kornstad L. Expression of A antigens on erythrocytes of weak blood group A subgroups. Vox Sang. 1994;66:231-236.
Québec Publications. M-9, r. 20.3-Règlement sur les dossiers, les lieux d'exercice et la cessation d'exercice d'un médecin. [cited 2022 July 13]. Available from: https://www.legisquebec.gouv.qc.ca/fr/document/rc/M-9,%20r.%2020.3